Today, 17 March 2020, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”). A summary of the resolutions follows. The resolution was passed with the required majority.
Approval of resolution to issue shares with preferential rights for existing shareholders
The Extraordinary General Meeting resolved to approve the Board of Directors’ resolution on 19 February 2020 to increase the company's share capital by not more than SEK 4,648,814.75 by a rights issue of not more than 92,976,295 shares with preferential rights for existing shareholders.
The right to subscribe for shares in the rights issue shall apply to persons whom on the record date for the rights issue are registered as shareholders in the company. One (1) existing share entitles to one (1) subscription right and two (2) subscription rights entitles to subscription of one (1) new share. The record date for determining which shareholders whom are entitled to subscribe for shares with preferential right shall be Wednesday 1 April 2020. Subscription of shares with subscription rights shall be made through payment in cash during the period from and including 6 April 2020 up to and including 24 April 2020. The Board of Directors shall have the right to extend the subscription and payment period. Notification of interest to subscribe for shares without subscription rights is possible during the subscription period. The subscription price per share is SEK 0.80.
Upon full subscription of the rights issue, the Company will raise approximately SEK 74 million before issuance costs.